![BIF](/sites/default/files/2023-05/230112-bio-bif-logo-color-horiz.jpg)
Eldec Pharmaceuticals, Inc. develops peptide-based therapies to treat lung infections/lung inflammation. Eldec is currently developing technology out-licensed from founder Rob Tarran’s lab at UNC. The Orai1 Ca2+ channel is a master regulator of the immune system. Dr. Tarran has developed a novel therapeutic that selectively and safely inhibits Orai1 in the lung lumen without affecting systemic immunity. Eldec’s lead development candidate, ELD607 is a fully-optimized peptidomimetic that negatively regulates Orai1 levels in lung immune cells. ELD607 exhibits beneficial immunomodulation function in a wide range of animal models of excessive inflammation and by preventing an exuberant immune response, helps clear pathogens from the lung. In addition, since Ca2+ also regulates viral replication, ELD607 has demonstrated potent anti-viral activity. Subsequent screening efforts have also identified ELD403, a naturally occurring sequence that has demonstrated potent anti-viral activity.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
North Carolina
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Respiratory
Lead Product in Development:
ELD607
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1